Argenx halts UNITY study while Argenx stock gains 1.22 percent

Published on 10/09/2026 at 12:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FB102 met its endpoint at p=0.0176 on October 8, 2026. Argenx stock trades at EUR 738.80 versus EUR 729.90, plus 1.22 percent, on October 9, 2026.

Key points in brief

Argenx halted the Phase 3 UNITY study on October 8, 2026, after an interim analysis found it unable to meet its primary endpoint.
FB102 met its Phase 2 celiac disease endpoint with p=0.0176 in a study of 126 patients.
Argenx stock was trading at EUR 738.80 at Lang & Schwarz on October 9, 2026, plus 1.22 percent versus the EUR 729.90 prior close.
The company plans to advance FB102 into Phase 3 development.

Extremmakro: Iridisierende blaue und violette Flüssigkeitstropfen auf einem Glasobjektträger, kristallscharfe Mitte mit weichem Bokeh, wissenschaftliche Abstraktion — Argenx NL0010832176 Extremmakro zeigt irisierende Flüssigkeitstropfen auf einem wissenschaftlichen Glas-Objektträger unter Laborlicht, Illustration mit AI erstellt.

Argenx (NL0010832176) was trading at EUR 738.80 at Lang & Schwarz on October 9, 2026 at 12:50 p.m. CEST, up 1.22 percent versus the EUR 729.90 prior close. On October 8, 2026, the company announced that it would discontinue the Phase 3 UNITY study in Sjögren's disease after an interim analysis found that the trial could not meet its primary endpoint, according to GlobeNewswire.

Two pipeline signals on October 8

The same October 8, 2026 update delivered a positive counterpoint. FB102 met the primary endpoint in a Phase 2 celiac disease study, with a statistically significant result at p=0.0176 versus placebo, and argenx plans to advance the program into Phase 3, GlobeNewswire reported.

The FB102-301 trial enrolled 126 adults with celiac disease. Participants received two dose levels of FB102 or placebo during an eight-week gluten challenge, making the result an early clinical data point rather than a commercial product milestone.

What does the setback mean for growth?

UNITY removes a late-stage opportunity for efgartigimod in Sjögren's disease, while the FB102 result adds a separate autoimmune development path. The contrast matters because the October 8 update affects both the lead franchise and pipeline diversification.

Investing.com reported on October 9, 2026 that Goldman Sachs trimmed its euro-denominated target from EUR 982.00 to EUR 954.00 while maintaining a Buy stance. The report also cited Wedbush's target change from USD 1,150.00 to USD 1,130.00, keeping an Outperform rating.

Stock remains volatile after the trial update

Argenx stock was trading at EUR 738.80 at Lang & Schwarz on October 9, 2026 at 12:50 p.m. CEST, plus 1.22 percent versus the EUR 729.90 prior close. The primary listing is on Euronext Brussels and Nasdaq, while the finance profile classifies the company in Healthcare and Biotechnology.

The further course of trading is shown by the continuously updated real-time quote of Argenx stock.